Information  X 
Enter a valid email address

EPIC/TIDM matching '0RQE'

Date
Time Source
Company
Announcement
10 Mar 2021 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia
03 Mar 2021 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
01 Mar 2021 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia submits NDA for clazosentan to Japanese PMDA
04 Feb 2021 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces financial results for 2020 – a successful year marked by outstanding clinical data
02 Feb 2021 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal
28 Jan 2021 4:45 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Invitation to Idorsia's full year financial results 2020 webcast and conference call
11 Jan 2021 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the near-term – Daridorexant NDA submitted to the US FDA
23 Nov 2020 4:45 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces positive results of the two Japanese registration studies with clazosentan
27 Oct 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces financial results for the first nine months of 2020
21 Oct 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million
20 Oct 2020 4:42 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces the results of its rights offering in the context of the capital increase
08 Oct 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified pipeline
02 Sep 2020 6:12 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
  6:05 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia assigns and transfers agreement with ReveraGen to Santhera
31 Aug 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States
28 Aug 2020 7:30 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
13 Aug 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
06 Aug 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia – preparation for a local registration program advancing
23 Jul 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces financial results for the first half 2020
16 Jul 2020 4:45 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Invitation to Idorsia's half year financial results 2020 webcast and conference call
  6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia establishes US commercial operations and leadership team
06 Jul 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces positive results in the second Phase 3 study of daridorexant
20 May 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia successfully completes the offering of new shares thereby securing funding for the company’s growth plan
19 May 2020 5:05 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia launches an offering of new shares to fund the company’s growth plan
13 May 2020 4:45 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia holds its third Annual General Meeting of Shareholders
12 May 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy
23 Apr 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces financial results for the first quarter 2020
20 Apr 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia
02 Apr 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia issues Notice of the 2020 Annual General Meeting of Shareholders
19 Mar 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Janssen announces submission of New Drug Application to the U.S. FDA for ponesimod for treatment of adults with relapsing multiple sclerosis
04 Mar 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Janssen submits European Marketing Authorization Application for ponesimod for treatment of adults with relapsing multiple sclerosis
06 Feb 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces financial results for 2019 – clinical programs advanced markedly – approaching first key results
30 Jan 2020 4:35 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Invitation to Idorsia's full year financial results 2019 webcast and conference call
10 Jan 2020 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy
05 Dec 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan
19 Nov 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel
11 Nov 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Encouraging Phase 2 data on cenerimod – Idorsia's S1P1 receptor modulator currently investigated for SLE – presented at ACR 2019
22 Oct 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces financial results for the first nine months of 2019
02 Oct 2019 4:35 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Data on cenerimod – Idorsia's S1P1 receptor modulator – will be presented at the ACR / ARP Annual Meeting 2019
11 Sep 2019 3:32 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis
03 Sep 2019 4:35 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019
31 Aug 2019 11:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Phase 2 data of aprocitentan, Idorsia’s dual endothelin receptor antagonist, presented at ESC 2019
23 Aug 2019 4:35 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 2019
26 Jul 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis
23 Jul 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces financial results for the first half of 2019
16 Jul 2019 4:35 pm GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Invitation to Idorsia's half year financial results 2019 webcast and conference call
13 Jun 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio
03 May 2019 12:26 pm GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved
18 Apr 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces financial results for the first quarter 2019
29 Mar 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia issues invitation to 2019 Annual General Meeting of Shareholders
07 Feb 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces financial results for 2018 - outstanding progress made - four late stage assets advanced into Phase 3
05 Feb 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
31 Jan 2019 4:35 pm GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Invitation to Idorsia's full year financial results 2018 webcast and conference call
07 Jan 2019 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus
18 Dec 2018 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective
20 Nov 2018 5:00 pm GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone
05 Nov 2018 6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia maintains collaboration agreement with ReveraGen
24 Oct 2018 4:36 pm GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Company statement
23 Oct 2018 6:02 am GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia financial results for the first nine months of 2018
  6:00 am GNW Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t